GlassScriptPhysician profile
Ryan Douglas Gilbert
NPI 1053773259
$1,740.54
in general payments reported to CMS, 2019-2025
28 companies · $659 in 2025
The $659 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.36 · 2022: $165 · 2023: $388 · 2024: $462 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $362.51 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $159.38 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.51 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $128.40 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $106.29 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $90.84 | 2022-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $83.06 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $80.15 | 2022-2023 | |
| Pfizer INC. | $75.50 | 2024-2025 | |
| Dexcom, INC. | $73.45 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $49.76 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $48.38 | 2019-2022 | |
| Nevro Corp. | $45.75 | 2024 | Senza |
| Sumitomo Pharma America, INC. | $38.48 | 2024-2025 | Gemtesa |
| Dynavax Technologies Corporation | $26.78 | 2024-2025 | Heplisav-B |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $25.24 | 2024 | Imcivree |
| Phathom Pharmaceuticals, INC. | $24.62 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $22.02 | 2025 | Injectafer |
| Shield Therapeutics INC | $21.72 | 2023 | Accrufer |
| Lilly USA, LLC | $20.84 | 2025 | Jardiance |
| Acadia Pharmaceuticals INC | $18.90 | 2025 | Nuplazid |
| Cvrx, INC. | $17.86 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $17.78 | 2019 | |
| Hologic Sales and Service, LLC | $17.64 | 2024 | Thinprep 2000 Processor, Aptima |
| Corcept Therapeutics | $15.38 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $15.18 | 2023 | Gvoke Hypopen |
| Cequr Corporation | $13.89 | 2023 | Cequr Simplicity |
| The Binding Site INC. | $7.23 | 2024 | Freelite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.